Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Aptose Biosciences (APTO).
Biogen (BIIB)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Biogen on November 30 and set a price target of $256.00. The company’s shares closed last Tuesday at $243.16, close to its 52-week low of $223.25.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.9% and a 49.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Biogen has an analyst consensus of Hold, with a price target consensus of $293.74, which is a 21.8% upside from current levels. In a report issued on November 30, Piper Sandler also maintained a Hold rating on the stock with a $265.00 price target.
See today’s analyst top recommended stocks >>
Aptose Biosciences (APTO)
RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences on November 30 and set a price target of $9.00. The company’s shares closed last Tuesday at $7.02.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 33.2% and a 68.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, ACADIA Pharmaceuticals, and Aprea Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $10.57 average price target, implying a 54.3% upside from current levels. In a report issued on November 17, Canaccord Genuity also maintained a Buy rating on the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
